Payment overview · 2025
General Payments
$383.32
22 reported records · 9 companies
Healthcare provider profile · identity verified
Clint M Colberg, MD
Allopathic & Osteopathic Physicians|Family Medicine · HOLTON, KS · NPI 1558337287
Verified facts
What the public records show
CMS Open Payments records show Clint M Colberg, MD received $383.32 in general payments during 2025 across 22 reported records.
Novartis Pharmaceuticals Corporation accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $126.95 | 33.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.47 | 13.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.27 | 11.6% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $42.45 | 11.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $31.29 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.39 | 7.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.09 | 5.8% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $18.88 | 4.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.53 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $383.32 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $126.95 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.27 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $42.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $18.88 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 238 | 61 |
| Lisinopril | Lisinopril | 190 | 48 |
| Potassium Chloride | Potassium Chloride | 166 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 37 |
| Omeprazole | Omeprazole | 140 | 39 |
| Metformin Hcl | Metformin Hcl | 132 | 31 |
| Losartan Potassium | Losartan Potassium | 127 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 124 | 32 |
| Gabapentin | Gabapentin | 123 | 22 |
| Furosemide | Furosemide | 114 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 30 |
| Eliquis | Apixaban | 95 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 17 |
| Ozempic | Semaglutide | 88 | 13 |
| Chlorthalidone | Chlorthalidone | 86 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 16 |
| Carvedilol | Carvedilol | 75 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 12 |
| Trazodone Hcl | Trazodone Hcl | 72 | 13 |
| Allopurinol | Allopurinol | 68 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | suppressed |
| Celecoxib | Celecoxib | 59 | 19 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Lorazepam | Lorazepam | 57 | 14 |
| Prednisone | Prednisone | 55 | 24 |
| Tramadol Hcl | Tramadol Hcl | 53 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 13 |
| Simvastatin | Simvastatin | 49 | 12 |
| Montelukast Sodium | Montelukast Sodium | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Diazepam | Diazepam | 44 | suppressed |
| Atenolol | Atenolol | 40 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Fentanyl | Fentanyl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 20 |
| Meloxicam | Meloxicam | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Glipizide | Glipizide | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Horizant | Gabapentin Enacarbil | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.32 · 22 records | Novartis Pharmaceuticals Corporation | CeQur Simplicity, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, LEQVIO, OTEZLA, Ozempic, REPATHA, SMARTVEST, UBRELVY, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error